Treatment of children with HIV infection.
The treatment of pediatric HIV infection has seen vast improvements in terms of better long-term suppression of HIV replication and subsequent improvements in the longevity and quality of life in children. This has been realized, in part, by development of newer antiretroviral medications, better knowledge about the pharmaco-kinetics of these drugs in children, and improved insight on drug toxicities in children. This review will discuss some of the newer agents that may be available for children in the near future, in addition to new pharmacokinetic and toxicity data that are specific to the pediatric patient. New information on key vaccines that should be administered to children with HIV infection is also discussed.
Dixon
Terry C
TC
Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA. dixon013@mc.duke.edu
Cunningham
Coleen K
CK
D016915:AIDS Vaccines; D000293:Adolescent; D044966:Anti-Retroviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data; D002648:Child; D002675:Child, Preschool; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000821:virology; D006801:Humans; D010372:Pediatrics / Q000639:trends; D014611:Vaccination
D016915:AIDS Vaccines; D044966:Anti-Retroviral Agents